MVP-104 Tetra-Specific

MVP-104 Tetra-Specific is a preclinical-stage tetraspecific antibody being developed by Multiverse Pharma for the treatment of oncology. The drug is designed as a T-cell engager (TCE) utilizing an IgG scaffold to simultaneously bind four distinct targets, thereby facilitating the recruitment and activation of T cells against tumor cells. While the specific molecular targets have not been publicly disclosed, the asset represents a multi-specific approach to oncology immunotherapy, aiming to enhance the precision and potency of immune-mediated tumor destruction. It is currently in the preclinical phase of development.

Other names

MVP-104MVP104MVP 104